NCT05696782 Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
| NCT ID | NCT05696782 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Nonsmall Cell Lung Cancer Stage III |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2023-07-26 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 28 participants in total. It began in 2023-07-26 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
Eligibility Criteria
Inclusion Criteria: * Patients must have stage II or stage III NSCLC confirmed by histologic or cytologic documentation and by clinical assessment. Staging is defined according to the AJCC Cancer Staging Manual, 8th Edition (2017). * Unresectable or medically inoperable as determined by the investigator. * The patient has definitive radiation therapy (e.g., 54 Gy to 66 Gy in 30 to 35 fractions) for lung cancer that is either (a) planned to start within the next 28 days, or (b) currently being administered, or (c) has been completed within the last 14 days. * Platinum-based chemotherapy for lung cancer that is either (a) planned to start within the next 28 days, (b) currently being administered, or (c) has been completed within the last 14 days. Chemotherapy must be for at least two cycles and be administered either before radiation therapy ("induction" or "sequential") or during radiation therapy ("concurrent"). * Consolidation durvalumab is planned for NSCLC after radiation and chemot
Frequently Asked Questions
Who can join the NCT05696782 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nonsmall Cell Lung Cancer Stage III. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05696782 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05696782 currently recruiting?
Yes, NCT05696782 is actively recruiting participants. Visit ClinicalTrials.gov or contact Wake Forest University Health Sciences to inquire about joining.
Where is the NCT05696782 trial being conducted?
This trial is being conducted at Winston-Salem, United States.
Who is sponsoring the NCT05696782 clinical trial?
NCT05696782 is sponsored by Wake Forest University Health Sciences. The trial plans to enroll 28 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.